Management is betting $500M on a second-half recovery while admitting their 3nm thesis collapses if volumes stay low.
Thesis: Teradyne is caught between a cyclical utilization collapse and a structural complexity shift. The Bull case relies on 3nm complexity forcing CapEx despite a downturn, but the CEO admitted that low volumes allow for 'high degree of reuse.' With OSAT utilization falling and the 'VIP' customer only at low-double-digits, the complexity floor hasn't been tested. The $500M buyback is the only hard floor.
Verdict: HOLD — Conviction: MEDIUM
Catalyst: Q2 earnings confirmation of the lead customer's 3nm ramp. If that demand firms, the H2 recovery thesis holds. If it pushes, the year is dead.
Key Risk: The 'high reuse' scenario. If 3nm volumes come in soft, customers optimize existing fleets instead of buying new testers, breaking the complexity thesis.
The Tell: CEO Greg Smith's admission on 3nm: "There is a scenario where if three nanometer volumes are low enough that they don't really need to buy new testers... because of this balance of units versus complexity."
Friction Level: HIGH_FRICTION — The complexity offset. Bulls believe 3nm complexity overrides unit declines. Bears point to 'high degree of reuse' and collapsing OSAT utilization.
Report not found
The report data is no longer available. Please return to the archive.